-
Sino Biopharmaceutical Reports H1 2023 Revenue Growth, Focus on Innovative Drugs
•
Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has released its financial report for the first half of 2023. The company recorded revenues of RMB 15.28 billion (USD 2 billion), marking a 0.5% increase year-on-year (YOY). Innovative drugs contributed significantly to the total revenues, generating RMB 3.86 billion…
-
Suzhou Novoprotein and Shanghai Model Organisms Center Ink Global Partnership
•
Suzhou Novoprotein Scientific Co., Ltd, (SHA: 688137) a leading provider of protein technology and application solutions in China, has entered into a strategic partnership with Shanghai Model Organisms Center, Inc. (SHA: 688265). The collaboration aims to combine the companies’ expertise on a global scale, focusing on technology and commerce. Novoprotein…
-
Sihuan Pharmaceutical Reports H1 2023 Revenue Dip Amid R&D Focus
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has released its financial report for the first half of 2023, recording revenues of RMB 1.0557 billion (USD 144 million), marking a 27.9% decrease year-on-year (YOY). The research and development (R&D) expenses for the period were RMB 294 million (USD 40 million), a…
-
CIRC Unveils FuZhi 1.0 Smart Nuclear Medicine System at Chinese Medical Association Meeting
•
China Isotope & Radiation Corporation (CIRC; HKG: 1763) has announced the launch of its innovative FuZhi 1.0 smart nuclear medicine system at the 2023 annual meeting of the Nuclear Medicine Branch of the Chinese Medical Association. This comprehensive system, which includes modules for smart patient care, smart nuclear drug management,…
-
Hunchun Port Designated as Medical Materials Import Port by NMPA and GAC
•
The National Medical Products Administration (NMPA) and the General Administration of Customs have jointly released a notification designating Hunchun Port in Jilin Province as a port for the import of medical materials. This designation signifies a strategic move to enhance the efficiency and management of medical imports in the region.…
-
Baxter Appoints Wu Xin as China General Manager Amid Spin-Off of Kidney Care Business
•
Baxter (NYSE: BAX), a leading provider of healthcare products, has announced the appointment of Wu Xin as its China General Manager, effective from October 7, as reported by MedTalent. This strategic move comes amidst the company’s spin-off of its global kidney care business and acute treatment business, which will operate…
-
China Grand Pharmaceutical Reports H1 2023 Revenues and Pipeline Progress
•
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has released its financial report for the first half of 2023, highlighting strong revenue growth and significant advancements in its clinical pipeline. The company recorded revenues of HKD 5.989 billion (USD 766 million) and net profits of HKD 1.124 billion…
-
EC Approves AbbVie’s Tepkinly for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
•
The European Commission (EC) has granted marketing approval to AbbVie (NYSE: ABBV) for its bispecific antibody (BsAb) Tepkinly (epcoritamab), a treatment for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adults who have undergone two or more lines of systemic therapy. This decision comes on the heels of…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
